Aromatase Inhibitors in Breast Cancer Prevention

Annals of Pharmacotherapy

Volumn 48, Issue 12, 2014, Pages 1605-1610

  Olin, Jacqueline L ^a   St Pierre, Melani ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

anastrozole; aromatase inhibitors; chemoprevention; exemestane; letrozole

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRILE; TRIAZOLE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CATARACT; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; HIGH RISK POPULATION; HUMAN; INFORMATION RETRIEVAL; LIFESTYLE MODIFICATION; MEDLINE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; BREAST NEOPLASMS; FEMALE; PATHOLOGY; RISK; TUMOR INVASION;

ANDROSTADIENES; ANTICARCINOGENIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NITRILES; POSTMENOPAUSE; RISK; TRIAZOLES;

EID: 84921508554     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028014548416     Document Type: Review

References (22)

1. Siegel R,Ma J,Zou Z,Jemal A.Cancer statistics, 2014.CA Cancer J Clin. 2014;64:9-29
2. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer risk reduction v.1.2014http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast_risk. Accessed July 31, 2014.
3. National Cancer Institute. Breast Cancer Risk Assessment Tool. Bethesda, MD: National Cancer Institute, US Department of Health and Human Services; 2011. http://www.cancer.gov/bcrisktool/Default.aspx. Accessed July 31, 2014.
4. Tyrer J,Duffy SW,Cuzick J.A breast cancer prediction model incorporating familial and personal risk factors.Stat Med. 2004;23:1111-1130
5. Moyer VA.Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2013;159:698-708
6. Vogel VG,Costantino JP,Wickerham DL, et al.Update of the national surgical adjuvant breast and bowel project Study of Tamoxifen And Raloxifene (STAR) P-2 trial: preventing breast cancer.Cancer Prev Res. 2010;3:696-706
7. Goss PE,Ingle JN,Ales-Martinez JE, et al.Exemestane for breast cancer prevention in postmenopausal women.N Engl J Med. 2011;364:2381-2391
8. Cuzick J,Sestak I,Dowsett M, et al.Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial.Lancet. 2014;383:1041-1048
9. Visvanathan K,Hurley P,Bantug E, et al.Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.J Clin Oncol. 2013;31:2942-2962
10. Lancet. 2007;369:2134
11. Pujol P,Lasset C,Berthet P, et al.Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.Fam Cancer. 2012;11:77-84
12. Exemestane and celecoxib in postmenopausal women at high risk for breast cancer (identifier: NCT00073073). http://clinicaltrials.gov/ct2/show/NCT00073073?term=NCT00073073&rank=1. Accessed August 12, 2014.
13. Chemoprevention trial: anastrozole in ductal carcinoma in situ (DCIS) in postmenopausal women (identifier: NCT00256217). http://clinicaltrials.gov/ct2/show/NCT00256217?term=NCT00256217&rank=1. Accessed August 12, 2014.
14. Letrozole in preventing breast cancer in postmenopausal women with a BRCA1 or BRCA2 mutation (LIBER) (identifier: NCT00673335). http://clinicaltrials.gov/ct2/show/NCT00673335?term=NCT00673335&rank=1. Accessed August 12, 2014.
15. Protocol for women at increased risk of developing breast cancer (identifier: NCT00291135). http://clinicaltrials.gov/ct2/show/NCT00291135?term=NCT00291135&rank=1. Accessed August 12, 2014.
16. Study of breast cancer prevention by letrozole in high risk women (identifier: NCT00579826). http://clinicaltrials.gov/ct2/show/NCT00579826?term=NCT00579826&rank=1. Accessed August 12, 2014.
17. Letrozole in postmenopausal women at increased risk for breast cancer (identifier: NCT00280930). http://clinicaltrials.gov/ct2/show/NCT00280930?term=NCT00280930&rank=1. Accessed August 12, 2014.
18. Letrozole in preventing breast cancer in postmenopausal women (identifier: NCT00090857). http://clinicaltrials.gov/ct2/show/NCT00090857?term=NCT00090857&rank=1. Accessed August 12, 2014.
19. Letrozole in preventing breast cancer in postmenopausal women who are at increased risk for breast cancer due to high breast density (identifier: NCT00238316). http://clinicaltrials.gov/ct2/show/NCT00238316?term=NCT00238316&rank=1. Accessed August 12, 2014.
20. Letrozole with or without zoledronate in treating healthy postmenopausal women with high breast density (identifier: NCT00114270). http://clinicaltrials.gov/ct2/show/NCT00114270?term=NCT00114270&rank=1. Accessed August 12, 2014.
21. Fabian CJ,Kimler BF,Zalles CM, et al.Reduction in proliferation with six months of letrozole in women on hormone replacement therapy.Breast Cancer Res Treat. 2007;106:75-84
22. Freeman AN,Yu B,Mitchell HG, et al.Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.J Clin Oncol. 2011;29:2327-2333